{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:56:40Z","timestamp":1791262600879,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["51191"],"award-info":[{"award-number":["51191"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110453","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:56:30Z","timestamp":1788155790000},"page":"110453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["New oxa\/thiadiazole-chalcone hybrids linked via a clickable 1,2,3-triazole bridge with dual EGFR\/VEGFR-2 kinase inhibitory activity and antiproliferative effects"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3083-1814","authenticated-orcid":false,"given":"Merit","family":"El-Qommos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-0451","authenticated-orcid":false,"given":"Rana M.I.","family":"Morsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1355-8380","authenticated-orcid":false,"given":"Hamdy M.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7908-2367","authenticated-orcid":false,"given":"Mostafa A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-8724","authenticated-orcid":false,"given":"Yaser A.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110453_bb0005","first-page":"1","article-title":"Global cancer statistics (2022): GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s40495-022-00289-6","article-title":"The effectiveness of various chemotherapeutic agents in cancer treatment","volume":"8","author":"Kashifa Fathima","year":"2022","journal-title":"Curr. Pharmacol. Rep."},{"issue":"33","key":"10.1016\/j.bioorg.2026.110453_bb0020","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.2174\/0929867325666180607094856","article-title":"Dual inhibitors as a new challenge for cancer multidrug resistance treatment","volume":"26","author":"Stankovi\u0107","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110453_rf0025","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14534","article-title":"Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy","volume":"103","author":"Budipramana","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110453_rf0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/ijo.2023.5474","article-title":"Dual inhibition of EGFR-VEGF: an effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation","volume":"62","author":"Wang","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110453_rf0035","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/15384101.2015.1022071","article-title":"VEGF and dual-EGFR inhibition in colorectal cancer","volume":"14","author":"Falchook","year":"2015","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110453_rf0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti\u2013VEGF and anti\u2013EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110453_bb0030","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0035","first-page":"50","article-title":"Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions","volume":"22","author":"Shah","year":"2021","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_bb0045","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules26041076","article-title":"Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR)","volume":"26","author":"Kaufman","year":"2021","journal-title":"Molecules"},{"issue":"72","key":"10.1016\/j.bioorg.2026.110453_bb0050","doi-asserted-by":"crossref","first-page":"44247","DOI":"10.1039\/D0RA09198G","article-title":"Prescribed drugs containing nitrogen heterocycles: an overview","volume":"10","author":"Heravi","year":"2020","journal-title":"RSC Adv."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110453_rf0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25147640","article-title":"The structure\u2013antiproliferative activity relationship of pyridine derivatives","volume":"25","author":"Villa-Reyna","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110453_rf0075","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2174\/1389557521666210614162031","article-title":"Pyridine moiety: an insight into recent advances in the treatment of cancer","volume":"22","author":"Sahu","year":"2022","journal-title":"Mini-Rev. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110453_bb0060","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/cbdd.13795","article-title":"1, 3, 4-oxadiazole and its derivatives: a review on recent progress in anticancer activities","volume":"97","author":"Vaidya","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_bb0065","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3390\/ph18040580","article-title":"Recent developments of 1, 3, 4-Thiadiazole compounds as anticancer agents","volume":"18","author":"Indelicato","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110453_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115254","article-title":"Recent updates on 1, 2, 3-triazole-containing hybrids with in vivo therapeutic potential against cancers: a mini-review","volume":"251","author":"Zhao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110453_rf0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109140","article-title":"The emerging role of Oxadiazole derivatives as VEGFR and EGFR inhibitors in Cancer therapy","author":"Nath","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110453_rf0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejmech.2015.04.051","article-title":"1, 3, 4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents","volume":"97","author":"Bajaj","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110453_rf0105","article-title":"4\u2010Thiadiazole Derivatives as VEGFR\u20102 Inhibitors and Its Molecular Insight for Cancer Therapy","volume":"1, 3","author":"Gawande","year":"2025","journal-title":"Chem. Biodivers."},{"issue":"48","key":"10.1016\/j.bioorg.2026.110453_rf0110","doi-asserted-by":"crossref","first-page":"40998","DOI":"10.1039\/D5RA03819G","article-title":"Current progress of 1, 2, 3-triazole hybrids as EGFR inhibitors for cancer therapy\u2013a literature review","volume":"15","author":"Khasawneh","year":"2025","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110453_rf0115","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/ml1001568","article-title":"Discovery of dual VEGFR-2 and tubulin inhibitors with in vivo efficacy","volume":"1","author":"Chekler","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_rf0120","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211066300","article-title":"A novel anti-lung cancer agent inhibits proliferation and epithelial\u2013mesenchymal transition","volume":"50","author":"Zhao","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.bioorg.2026.110453_rf0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143907","article-title":"Exploring 1, 3, 4-oxadiazole-chalcone hybrids as dual EGFR-resistant mutant inhibitors and antioxidants through in-silico and synthetic approaches","volume":"1349","author":"Patil","year":"2026","journal-title":"J. Mol. Struct."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_rf0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jccs.70025","article-title":"Substituted 1, 3, 4-oxadiazole coupled 1, 2, 3-triazole derivatives as antiproliferative agents: Design, synthesis, biological evaluation and in silico studies","volume":"72","author":"Gandamalla","year":"2025","journal-title":"J. Chin. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_rf0135","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200009","article-title":"New 1, 3, 4-oxadiazoles linked with the 1, 2, 3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase","volume":"355","author":"Mahmoud","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110453_rf0140","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s13738-025-03276-y","article-title":"Design and evaluation of pyridine-linked 1,3,4-oxadiazole-triazole heterocycles: a synthetic, computational and biological study","volume":"22","author":"Poojary","year":"2025","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110453_rf0145","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s13738-025-03276-y","article-title":"Design and evaluation of pyridine-linked 1,3,4-oxadiazole-triazole heterocycles: a synthetic, computational and biological study","volume":"22","author":"Poojary","year":"2025","journal-title":"J. Iran. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_rf0150","doi-asserted-by":"crossref","first-page":"2200009","DOI":"10.1002\/ardp.202200009","article-title":"New 1, 3, 4-oxadiazoles linked with the 1, 2, 3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase","volume":"355","author":"Mahmoud","year":"2022","journal-title":"Arch. Pharm."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110453_rf0155","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/ml1001568","article-title":"Discovery of dual VEGFR-2 and tubulin inhibitors with in vivo efficacy","volume":"1","author":"Chekler","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_rf0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jccs.70025","article-title":"Substituted 1, 3, 4-oxadiazole coupled 1, 2, 3-triazole derivatives as antiproliferative agents: Design, synthesis, biological evaluation and in silico studies","volume":"72","author":"Gandamalla","year":"2025","journal-title":"J. Chin. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110453_rf0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143907","article-title":"Exploring 1, 3, 4-oxadiazole-chalcone hybrids as dual EGFR-resistant mutant inhibitors and antioxidants through in-silico and synthetic approaches","volume":"1349","author":"Patil","year":"2026","journal-title":"J. Mol. Struct."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_rf0170","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211066300","article-title":"A novel anti-lung cancer agent inhibits proliferation and epithelial\u2013mesenchymal transition","volume":"50","author":"Zhao","year":"2022","journal-title":"J. Int. Med. Res."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110453_bb0100","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543776.2020.1811853","article-title":"Antibacterial carbonic anhydrase inhibitors: an update on the recent literature","volume":"30","author":"Supuran","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110453_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/molecules31020355","article-title":"Triazole and pyrazole hybrids of electrophilic natural products as promising anticancer agents","volume":"31","author":"Fermo","year":"2026","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110453_bb0110","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1021\/acs.jmedchem.4c00652","article-title":"Triazoles in medicinal chemistry: physicochemical properties, bioisosterism, and application","volume":"67","author":"Guan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100158","article-title":"1, 2, 3-triazole hybrids as anticancer agents: A review","volume":"355","author":"Alam","year":"2022","journal-title":"Arch. Pharm."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110453_rf0195","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3390\/molecules30112395","article-title":"Flavonoids, chalcones, and their fluorinated derivatives\u2014recent advances in synthesis and potential medical applications","volume":"30","author":"Kubiak","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110453_rf0200","doi-asserted-by":"crossref","first-page":"1570385","DOI":"10.3389\/fphar.2025.1570385","article-title":"Pharmacological potential of natural chalcones: a recent studies and future perspective","volume":"16","author":"Adhikari","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110453_rf0205","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1039\/D5RA01280E","article-title":"Excavating medicinal virtues of chalcones to illuminate a new scope in cancer chemotherapy","volume":"15","author":"Nivedya","year":"2025","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_rf0210","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/17568919.2025.2458450","article-title":"Therapeutic potential of chalcone-1, 2, 3-triazole hybrids as anti-tumour agents: a systematic review and SAR studies","volume":"17","author":"Priya","year":"2025","journal-title":"Future Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_bb0130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/17460441.2024.2322990","article-title":"Molecular hybridization: a powerful tool for multitarget drug discovery","volume":"19","author":"de Sena Murteira Pinheiro","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110453_bb0135","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1016\/j.ejmech.2009.03.023","article-title":"Synthesis of new chiral 2, 5-disubstituted 1, 3, 4-thiadiazoles possessing \u03b3-butenolide moiety and preliminary evaluation of in vitro anticancer activity","volume":"44","author":"Wei","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_bb0140","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jhet.1060","article-title":"Synthesis and evaluation of antimicrobial activity of some new hetaryl-azoles derivatives obtained from 2-Aryl-4-methylthiazol-5-carbohydrazides and Isonicotinic acid hydrazide","volume":"49","author":"Tiperciuc","year":"2012","journal-title":"J. Heterocyclic Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110453_bb0145","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3184\/174751916X14761050193688","article-title":"Synthesis of novel antiproliferative 1, 2, 3-triazole hybrids using the molecular hybridisation approach","volume":"40","author":"Fu","year":"2016","journal-title":"J. Chem. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110453_bb0150","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1021\/ol070527h","article-title":"Efficient conversion of aromatic amines into azides: A one-pot synthesis of triazole linkages","volume":"9","author":"Barral","year":"2007","journal-title":"Org. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110453_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126846","article-title":"The bioisosteric modification of pyrazinamide derivatives led to potent antitubercular agents: synthesis via click approach and molecular docking of pyrazine-1, 2, 3-triazoles","volume":"30","author":"Reddyrajula","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110453_bb0160","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1007\/s00044-014-1007-z","article-title":"Synthesis, anti-inflammatory and antioxidant activity of ring-A-monosubstituted chalcone derivatives","volume":"23","author":"Iqbal","year":"2014","journal-title":"Med. Chem. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0165","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1515\/zpch-1989-270148","article-title":"Zum Substituenteneinflu\u00df auf die UV-VIS-spektroskopischen Eigenschaften von Mono- und Bisaziden","volume":"270O","author":"Sauer","year":"1989","journal-title":"Z. Phys. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cmdc.201200355","article-title":"Thiadiazole\u2014a promising structure in medicinal chemistry","volume":"8","author":"Li","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110453_bb0175","author":"Natarajan"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110453_bb0180","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/molecules24081557","article-title":"Future prospects in the treatment of parasitic diseases: 2-amino-1, 3, 4-thiadiazoles in leishmaniasis","volume":"24","author":"Serban","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110453_bb0185","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.acthis.2018.02.005","article-title":"Tetrazolium salts and formazan products in cell biology: viability assessment, fluorescence imaging, and labeling perspectives","volume":"120","author":"Stockert","year":"2018","journal-title":"Acta Histochem."},{"key":"10.1016\/j.bioorg.2026.110453_bb0190","series-title":"Cytotoxicity-understanding cellular damage and response","article-title":"Colorimetric Cytotoxicity Assays","author":"Karatop","year":"2022"},{"key":"10.1016\/j.bioorg.2026.110453_bb0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110453_bb0200","series-title":"StatPearls [Internet]","article-title":"Biochemistry, epidermal growth factor receptor","author":"Murphrey","year":"2023"},{"issue":"19","key":"10.1016\/j.bioorg.2026.110453_bb0205","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3390\/cells13191656","article-title":"Advances in cancer therapy: a comprehensive review of CDK and EGFR inhibitors","volume":"13","author":"Hawash","year":"2024","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110453_bb0210","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/13543776.2021.1935872","article-title":"An updated patent review of VEGFR-2 inhibitors (2017-present)","volume":"31","author":"Farghaly","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_bb0215","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.3390\/ijms23063375","article-title":"Relationship between VEGF family members, their receptors and cell death in the neoplastic transformation of colorectal cancer","volume":"23","author":"Dakowicz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110453_bb0220","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1080\/10406638.2021.1886123","article-title":"Current advancement in the oxadiazole-based scaffolds as anticancer agents","volume":"42","author":"Kapoor","year":"2022","journal-title":"Polycycl. Aromat. Compd."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_bb0225","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/17415993.2021.1963441","article-title":"Synthetic and anti-cancer activity aspects of 1, 3, 4-thiadiazole containing bioactive molecules: a concise review","volume":"42","author":"Obakachi","year":"2021","journal-title":"J. Sulfur Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110453_bb0230","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/ph18050625","article-title":"Anti-leukemic profiling of oxazole-linked oxadiazole derivatives: a computational and kinetic approach","volume":"18","author":"Khowdiary","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110453_bb0235","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","article-title":"Combinatorial strategies to target RAS-driven cancers","volume":"24","author":"Perurena","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_bb0240","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.3390\/ijms24043674","article-title":"Basic methods of cell cycle analysis","volume":"24","author":"Ligasov\u00e1","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110453_bb0245","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.3390\/ijms21186479","article-title":"Targeting cell cycle in breast cancer: CDK4\/6 inhibitors","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110453_bb0250","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jmgm.2009.08.012","article-title":"Induced-fit docking studies of the active and inactive states of protein tyrosine kinases","volume":"28","author":"Zhong","year":"2009","journal-title":"J. Mol. Graph. Model."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100542","article-title":"Recent advances in the prediction of pharmacokinetics properties in drug design studies: a review","volume":"17","author":"Pantale\u00e3o","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110453_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.160423","article-title":"Minimizing late-stage failure in drug development with transformer models: enhancing drug screening and pharmacokinetic predictions","volume":"508","author":"Khambhawala","year":"2025","journal-title":"Chem. Eng. J."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_bb0265","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/molecules25061375","article-title":"A review on applications of computational methods in drug screening and design","volume":"25","author":"Lin","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110453_bb0270","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3390\/ijms23020811","article-title":"The SwissSimilarity 2021 web tool: novel chemical libraries and additional methods for an enhanced ligand-based virtual screening experience","volume":"23","author":"Bragina","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110453_bb0275","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110453_bb0280","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1021\/om100106e","article-title":"NMR chemical shifts of trace impurities: common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist","volume":"29","author":"Fulmer","year":"2010","journal-title":"Organometallics"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110453_bb0285","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s13738-021-02358-x","article-title":"Synthesis of novel seco-acyclo-N-diazolyl-thione nucleosides analogous derived from acetic acid: characterization, complex formation with ions Pb (II), Hg (II) and antibacterial activity","volume":"19","author":"Chehrouri","year":"2022","journal-title":"J. Iran. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110453_bb0290","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1007\/s11164-013-1505-5","article-title":"Nitrite ionic liquid as a new reagent for in situ synthesis of aryl iodides and azides","volume":"41","author":"Eshghi","year":"2015","journal-title":"Res. Chem. Intermed."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110453_bb0295","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/jhet.4331","article-title":"Synthesis and bioactivity evaluation of eugenol hybrids obtained by Mannich and 1, 3 dipolar cycloaddition reactions","volume":"58","author":"Buduma","year":"2021","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2026.110453_bb0300","author":"Kalhor Monfared","year":"2014"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s43046-020-00026-4","article-title":"Anticancer effects induced by artichoke extract in oral squamous carcinoma cell lines","volume":"32","author":"Hassabou","year":"2020","journal-title":"J. Egypt. Natl. Canc. Inst."},{"key":"10.1016\/j.bioorg.2026.110453_bb0310","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.21608\/edj.2018.78894","article-title":"Investigation the cytotoxicity and apoptosis of Annonaceae nanoparticles and 5-FU encapsulated chitosan nanoparticles against tongue squamous cell carcinoma cell lines (SSC-25)","volume":"64","author":"Zayed","year":"2018","journal-title":"Egypt. Dent. J."},{"issue":"48","key":"10.1016\/j.bioorg.2026.110453_bb0315","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"45","key":"10.1016\/j.bioorg.2026.110453_bb0320","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110453_bb0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110453_bb0330","first-page":"57","article-title":"Python: a programming language for software integration and development","volume":"17","author":"Sanner","year":"1999","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2026.110453_bb0335","series-title":"version 2021.2.1, Advanced Chemistry Development","author":"ChemSketch","year":"2021"},{"key":"10.1016\/j.bioorg.2026.110453_bb0340","series-title":"Discovery studio visualizer","author":"BIOVIA: Dassault Syst\u00e8mes","year":"2024"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110453_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:29:32Z","timestamp":1791260972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":86,"alternative-id":["S0045206826009892"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110453","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New oxa\/thiadiazole-chalcone hybrids linked via a clickable 1,2,3-triazole bridge with dual EGFR\/VEGFR-2 kinase inhibitory activity and antiproliferative effects","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110453"}}